N4 Pharma PLC Grant of Options
28 Novembro 2024 - 4:00AM
RNS Regulatory News
RNS Number : 9339N
N4 Pharma PLC
28 November 2024
28 November 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
Grant of
Options
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments, gene therapy and vaccines,
announces that, on 27 November 2024, the Board granted 15 million
options (the "Options") over ordinary shares of 0.4p each in the
Company to certain directors of N4 Pharma as follows:
|
Director
|
|
Number of options
granted
|
|
|
|
|
|
Nigel Theobold (Chief Executive
Officer)
|
|
6,000,000
|
|
Michael Palfreyman (Non-Executive
Director)
|
|
3,000,000
|
|
Dr Chris Britten (Non-Executive
Chairman)
|
|
3,000,000
|
|
Luke Cairns (Executive
Director)
|
|
3,000,000
|
The Options have an exercise price
of 0.75p and vest in three equal tranches on the first, second and
third anniversaries from the date of grant. The Options have
a term of ten years from the date of grant.
The FCA notifications, made in
accordance with the requirements of the Market Abuse Regulation,
are appended below.
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Engage with us directly at N4 Pharma
Investor Hub
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary
Nanogenics.
N4 Pharma's business model is to
partner with companies developing products in these fields to use
Nuvec® or Liptide® as the delivery vehicle for these products. As
these products progress through pre‐clinical and clinical programs,
N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the
Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Nigel Theobold
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
N4 Pharma plc
|
|
b)
|
LEI
|
213800I841D2RKMFK955
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.4p
each
Identification code (ISIN) for N4
Pharma plc ordinary shares: GB00BYW8QM32
|
|
b)
|
Nature of the transaction
|
Issue of options over ordinary shares
of 0.4p each
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.75p exercise price
|
6,000,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
27 November 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Michael Palfreyman
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
N4 Pharma plc
|
|
b)
|
LEI
|
213800I841D2RKMFK955
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.4p
each
Identification code (ISIN) for N4
Pharma plc ordinary shares: GB00BYW8QM32
|
|
b)
|
Nature of the transaction
|
Issue of options over ordinary shares
of 0.4p each
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.75p exercise price
|
3,000,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
27 November 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Chris Britten
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
N4 Pharma plc
|
|
b)
|
LEI
|
213800I841D2RKMFK955
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.4p
each
Identification code (ISIN) for N4
Pharma plc ordinary shares: GB00BYW8QM32
|
|
b)
|
Nature of the transaction
|
Issue of options over ordinary shares
of 0.4p each
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.75p exercise price
|
3,000,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
27 November 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Luke Cairns
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
N4 Pharma plc
|
|
b)
|
LEI
|
213800I841D2RKMFK955
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Options over Ordinary Shares of 0.4p
each
Identification code (ISIN) for N4
Pharma plc ordinary shares: GB00BYW8QM32
|
|
b)
|
Nature of the transaction
|
Issue of options over ordinary shares
of 0.4p each
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0.75p exercise price
|
3,000,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
27 November 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHEAEFXAEDLFAA
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
